5686 related articles for article (PubMed ID: 3781914)
1. Antitumor activity of spergualin, a novel antitumor antibiotic.
Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1986 Oct; 39(10):1461-6. PubMed ID: 3781914
[TBL] [Abstract][Full Text] [Related]
2. Antitumor spectrum of deoxyspergualin and its lack of cross-resistance to other antitumor agents.
Nishikawa K; Shibasaki C; Hiratsuka M; Arakawa M; Takahashi K; Takeuchi T
J Antibiot (Tokyo); 1991 Oct; 44(10):1101-9. PubMed ID: 1955393
[TBL] [Abstract][Full Text] [Related]
3. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
Umezawa H; Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T
Cancer Res; 1987 Jun; 47(12):3062-5. PubMed ID: 3495325
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Fujimoto S; Ogawa M
Cancer Chemother Pharmacol; 1982; 8(2):157-62. PubMed ID: 7105379
[TBL] [Abstract][Full Text] [Related]
5. [Spergualin, a new antitumor antibiotic].
Takeuchi T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):845-9. PubMed ID: 3566295
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
[TBL] [Abstract][Full Text] [Related]
7. Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent.
Schurig JE; Rose WC; Kamei H; Nishiyama Y; Bradner WT; Stringfellow DA
Invest New Drugs; 1990 Feb; 8(1):7-15. PubMed ID: 2345072
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.
Harrison SD; Brockman RW; Trader MW; Laster WR; Griswold DP
Invest New Drugs; 1987 Dec; 5(4):345-51. PubMed ID: 3436739
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
10. Experimental antitumor activity of BMY-28090, a new antitumor antibiotic.
Schurig JE; Bradner WT; Basler GA; Rose WC
Invest New Drugs; 1989 Jul; 7(2-3):173-8. PubMed ID: 2793369
[TBL] [Abstract][Full Text] [Related]
11. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Ueda H; Manda T; Matsumoto S; Mukumoto S; Nishigaki F; Kawamura I; Shimomura K
J Antibiot (Tokyo); 1994 Mar; 47(3):315-23. PubMed ID: 8175484
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of newly isolated antibiotics, 3-dichloromethylactinobolins.
Okumoto T; Kontani M; Hoshino H; Nakanishi M
J Pharmacobiodyn; 1980 Mar; 3(3):177-82. PubMed ID: 7205539
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26.
Chiuten DF; Muggia FM; Johnson RK
Cancer Treat Rep; 1979; 63(11-12):1857-62. PubMed ID: 93512
[No Abstract] [Full Text] [Related]
14. Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
Mabel JA; Wodinsky I
Cancer; 1983 Feb; 51(4):600-5. PubMed ID: 6401590
[TBL] [Abstract][Full Text] [Related]
15. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.
Zylicz Z; Wagener DJ; van Rennes H; van der Kleijn E; Lelieveld P; van den Broek LA; Ottenheijm HC
Invest New Drugs; 1988 Dec; 6(4):285-92. PubMed ID: 3229941
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
Goldin A; Venditti JM; Geran R
Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a new fluoropyrimidine derivative, 5'-deoxy-5-fluorouridine, against murine and human experimental tumors.
Fujimoto S; Wang Y; Inoue K; Ogawa M
Jpn J Cancer Res; 1985 Jul; 76(7):644-50. PubMed ID: 3161854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
